Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 357.6 INR -1.25% Market Closed
Market Cap: 243.2B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Natco Pharma Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natco Pharma Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Natco Pharma Ltd
NSE:NATCOPHARM
Retained Earnings
â‚ą58.2B
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
24%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Retained Earnings
â‚ą281.7B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Retained Earnings
â‚ą282B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Retained Earnings
â‚ą688.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Retained Earnings
â‚ą73.4B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
12%
M
Mankind Pharma Ltd
NSE:MANKIND
Retained Earnings
â‚ą92.7B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Natco Pharma Ltd
Glance View

Market Cap
243B INR
Industry
Pharmaceuticals

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

NATCOPHARM Intrinsic Value
681.5 INR
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Natco Pharma Ltd's Retained Earnings?
Retained Earnings
58.2B INR

Based on the financial report for Jun 30, 2024, Natco Pharma Ltd's Retained Earnings amounts to 58.2B INR.

What is Natco Pharma Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
24%

Over the last year, the Retained Earnings growth was 20%. The average annual Retained Earnings growth rates for Natco Pharma Ltd have been 13% over the past three years , 11% over the past five years , and 24% over the past ten years .

Back to Top